DMAC

DiaMedica Therapeutics Inc

Sep 18 • 04:00PM ET

6.76

-0.11 -1.60 %

Healthcare • Biotechnology • USA • NASD

Peers: BMRN RNA EBS ARWR AKBA ALKS RIGL LGND AKRO ANVS

| Held by: VTI IWM VXF IWO VTWO IWC VTWG RSSL AVSC URTY

Index	RUT	P/E	-	EPS (ttm)	-0.69	Insider Own	63.47%	Shs Outstand	43.07M	Perf Week	-7.14%
Market Cap	349.41M	Forward P/E	-	EPS next Y	-0.74	Insider Trans	21.48%	Shs Float	24.55M	Perf Month	17.16%
Enterprise Value	319.66M	PEG	-	EPS next Q	-0.16	Inst Own	17.35%	Short Float	16.42%	Perf Quarter	76.96%
Income	-29.58M	P/S	-	EPS this Y	-13.33%	Inst Trans	19.82%	Short Ratio	9.49	Perf Half Y	29.01%
Sales	0.00M	P/B	10.72	EPS next Y	-9.31%	ROA	-67.03%	Short Interest	4.03M	Perf YTD	24.49%
Book/sh	0.63	P/C	11.63	EPS next 5Y	-6.51%	ROE	-73.41%	52W High	7.49 -9.75%	Perf Year	50.56%
Cash/sh	0.58	P/FCF	-	EPS past 3/5Y	2.58% 7.39%	ROIC	-108.14%	52W Low	3.19 111.91%	Perf 3Y	359.86%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.67% 6.09%	Perf 5Y	65.69%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-31.78%	Oper. Margin	-	ATR (14)	0.42	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.55	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	61.23	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.55	EPS Q/Q	-33.23%	SMA20	6.24%	Beta	1.39	Target Price	12.33
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	25.16%	Rel Volume	1.01	Prev Close	6.87
Employees	28	LT Debt/Eq	0.01	Earnings	Aug 12 AMC	SMA200	35.84%	Avg Volume	424.92K	Price	6.76
IPO	Jan 04, 2008	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.26% -	Trades		Volume	430,605	Change	-1.60%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-24	Initiated	H.C. Wainwright	Buy	$7
Apr-24-24	Resumed	Craig Hallum	Buy	$8
Jun-22-23	Upgrade	Oppenheimer	Perform → Outperform	$7
Apr-09-21	Initiated	Oppenheimer	Outperform	$27
Feb-17-21	Initiated	ROTH Capital	Buy	$38
Oct-30-20	Initiated	Guggenheim	Buy	$16
Jul-08-20	Initiated	Maxim Group	Buy	$14
Apr-30-19	Initiated	Dougherty & Company	Buy	$8
Mar-05-19	Initiated	Lake Street	Buy	$9

Sep-17-25 12:00PM	DiaMedica Therapeutics, Inc. (DMAC) is a Great Momentum Stock: Should You Buy? (Zacks)
Sep-09-25 09:55AM	After Golden Cross, DiaMedica Therapeutics, Inc. (DMAC)'s Technical Outlook is Bright (Zacks)
Sep-08-25 05:04PM	Wall Street Analysts Believe DiaMedica Therapeutics (DMAC) Could Rally 100.81%: Here's is How to Trade (Zacks) +16.61%
Sep-05-25 08:30AM	DiaMedica Therapeutics to Participate in Upcoming Investor Conferences (Business Wire) +14.34%
Sep-02-25 08:23AM	DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference (Business Wire) -6.83%
12:00PM	Loading…
Aug-28-25 12:00PM	What Makes DiaMedica Therapeutics, Inc. (DMAC) a Strong Momentum Stock: Buy Now? (Zacks)
Aug-19-25 09:55AM	Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect? (Zacks)
Aug-12-25 04:15PM	DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights (Business Wire) +13.97% +14.94%
Aug-06-25 08:00AM	DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer (Business Wire) +5.12%
Aug-05-25 04:15PM	DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025 (Business Wire)
Jul-23-25 04:30PM	DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement (Business Wire) +11.96% -5.24%
Jul-21-25 08:00AM	DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline (Business Wire) +8.61%
Jul-17-25 08:00AM	DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer (Business Wire)
Jun-24-25 08:30AM	DiaMedica Therapeutics Announces Inclusion in the Russell 2000 and Russell 3000 Indexes (Business Wire)
May-22-25 08:30AM	DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025 (Business Wire)
09:00AM	Loading…
May-19-25 09:00AM	DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia (Business Wire)
May-15-25 03:09AM	DiaMedica Therapeutics Inc (DMAC) Q1 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
May-14-25 11:14PM	Q1 2025 DiaMedica Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
04:30PM	DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference ESOC 2025 (Business Wire)
May-13-25 04:30PM	DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights (Business Wire)
May-08-25 04:00PM	DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May (Business Wire)
May-07-25 08:30AM	DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025 (Business Wire)
Apr-15-25 08:54PM	DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve (Seeking Alpha)
Mar-19-25 03:00AM	DiaMedica Therapeutics Inc (DMAC) Q4 2024 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
Mar-18-25 10:22PM	Q4 2024 DiaMedica Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -13.02%
Mar-17-25 04:30PM	DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results (Business Wire)
Mar-11-25 08:23AM	DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025 (Business Wire)
Feb-24-25 08:30AM	DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors (Business Wire)
Feb-20-25 08:15AM	DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke (Business Wire)
Feb-10-25 04:15PM	DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
08:25AM	Loading…
Dec-03-24 08:25AM	DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia (Business Wire)
Nov-15-24 02:06AM	Q3 2024 DiaMedica Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-13-24 04:20PM	DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results (Business Wire)
04:05PM	DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia (Business Wire)
Nov-12-24 08:23AM	DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference (Business Wire)
Nov-06-24 08:32AM	DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 (Business Wire)
Oct-10-24 05:28AM	DiaMedica gets SAHPRA approval for Phase II preeclampsia treatment trial (Clinical Trials Arena)
Oct-09-24 08:27AM	DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia (Business Wire)
Sep-04-24 04:15PM	DiaMedica Therapeutics Upcoming Conference Participation (Business Wire)
Aug-07-24 04:15PM	DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results (Business Wire)
Aug-01-24 09:40AM	Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year? (Zacks) +5.18%
08:20AM	DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024 (Business Wire)
Jul-11-24 08:00AM	DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia (Business Wire) +6.67%
Jul-01-24 08:00AM	DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement (Business Wire)
Jun-26-24 08:15AM	DiaMedica Therapeutics Announces $11.8 Million Private Placement (Business Wire) +30.97%
08:00AM	DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia (Business Wire)
May-13-24 12:08PM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 10:54PM	DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -5.19% -6.34%
04:30PM	DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results (Business Wire)
May-02-24 08:55AM	DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024 (Business Wire)
Apr-18-24 10:06AM	DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch (Zacks)
Apr-17-24 04:08PM	DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke (Business Wire) +9.70%
Apr-15-24 09:35AM	DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-25-24 10:00AM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-23-24 06:00AM	Wall Streets Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich (InvestorPlace)
Mar-19-24 09:53PM	DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023 (InvestorPlace)
04:15PM	DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results (Business Wire)
Jan-29-24 04:13PM	DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference (Business Wire)
Jan-22-24 08:23AM	DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer (Business Wire)
Dec-04-23 02:56PM	Billionaire Lee Coopermans 10 Stock Picks with Huge Upside Potential (Insider Monkey)
Nov-15-23 12:15PM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 10:54PM	Q3 2023 DiaMedica Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +6.84%
02:53PM	DiaMedica Therapeutics Inc. (DMAC) Reports Third Quarter 2023 Financial Results (GuruFocus.com)
Nov-13-23 04:28PM	DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results (Business Wire)
Nov-09-23 08:25AM	DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023 (Business Wire)
Nov-06-23 08:23AM	DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023 (Business Wire)
Sep-12-23 08:13AM	DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer (Business Wire)
Sep-06-23 08:35AM	DiaMedica Therapeutics to Participate at Lake Streets 7th Annual Best Ideas Growth Conference (Business Wire)
Aug-31-23 09:40AM	Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-15-23 09:19PM	Q2 2023 DiaMedica Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 04:13PM	DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results (Business Wire)
Aug-08-23 08:32AM	DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023 (Business Wire)
Jul-18-23 08:30AM	DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference (Business Wire)
Jun-26-23 08:30AM	DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement (Business Wire)
Jun-21-23 08:39AM	DiaMedica Therapeutics Announces $37.5 Million Private Placement (Business Wire) -6.91%
08:15AM	DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke (Business Wire)
May-30-23 08:29AM	DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors (Business Wire)
May-17-23 01:50PM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-16-23 09:38PM	Q1 2023 DiaMedica Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -10.77%
May-15-23 04:28PM	DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results (Business Wire) +22.72%
May-13-23 09:23AM	Bullish DiaMedica Therapeutics Insiders Loaded Up On US$5.2m Of Stock \ (Simply Wall St.)
May-08-23 08:50AM	DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023 (Business Wire)
Apr-11-23 08:41AM	DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer (Business Wire)
Mar-31-23 04:29AM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-28-23 04:30PM	DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results (Business Wire)
Mar-20-23 04:17PM	DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023 (Business Wire)
Mar-13-23 08:00AM	DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference (Business Wire)
Mar-06-23 08:30AM	DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors (Business Wire)
Dec-31-22 08:02AM	We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth (Simply Wall St.)
Dec-04-22 07:04AM	Insider Buying: The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Independent Director Just Bought 38% More Shares (Simply Wall St.)
Nov-09-22 04:15PM	DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results (Business Wire)
Nov-07-22 08:32AM	DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022 (Business Wire)
Nov-02-22 12:00PM	What Makes DiaMedica Therapeutics, Inc. (DMAC) a New Buy Stock (Zacks)
Oct-31-22 08:32AM	DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference (Business Wire)
Oct-26-22 04:30PM	DiaMedica Therapeutics Provides Update on ReMEDy2 Trial (Business Wire) -15.49%
Oct-14-22 09:49AM	Insiders rewarded with a US$114k addition on top of their US$676k purchase as DiaMedica Therapeutics Inc. (NASDAQ:DMAC) hits US$41m (Simply Wall St.)
Sep-14-22 08:30AM	DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations (Business Wire) +8.16%
Sep-06-22 04:10PM	DiaMedica Therapeutics to Present at Lake Streets 6th Annual Best Ideas Growth Conference (Business Wire) -21.02%
Aug-10-22 05:20PM	DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results (Business Wire) +9.83%
Aug-04-22 08:12AM	DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022 (Business Wire) +5.59%

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
STAHLBERG JAN	10% Owner	Aug 25 '25	Buy	6.00	338,265	2,029,252	7,654,045	Sep 04 02:29 PM
STAHLBERG JAN	10% Owner	Aug 13 '25	Buy	5.91	293,601	1,734,918	7,058,066	Sep 04 02:29 PM
STAHLBERG JAN	10% Owner	Aug 14 '25	Buy	5.99	70,414	421,921	7,128,480	Sep 04 02:29 PM
STAHLBERG JAN	10% Owner	Aug 20 '25	Buy	5.86	71,107	416,495	7,207,820	Sep 04 02:29 PM
STAHLBERG JAN	10% Owner	Aug 26 '25	Buy	6.00	59,648	357,888	7,713,693	Sep 04 02:29 PM
STAHLBERG JAN	10% Owner	Aug 22 '25	Buy	5.96	59,788	356,576	7,315,780	Sep 04 02:29 PM
STAHLBERG JAN	10% Owner	Aug 27 '25	Buy	6.00	50,772	304,632	7,764,465	Sep 04 02:29 PM
STAHLBERG JAN	10% Owner	Aug 21 '25	Buy	5.96	48,172	287,028	7,255,992	Sep 04 02:29 PM
STAHLBERG JAN	10% Owner	Aug 15 '25	Buy	6.00	8,233	49,398	7,136,713	Sep 04 02:29 PM
STAHLBERG JAN	10% Owner	Jul 23 '25	Buy	3.50	1,542,857	5,400,000	6,764,465	Jul 25 06:54 PM
Von Koch Thomas	10% Owner	Jul 23 '25	Buy	3.50	2,857,142	9,999,997	8,383,577	Jul 25 05:49 PM
JACINTO RICHARD II	10% Owner	Jul 23 '25	Buy	3.50	400,000	1,400,000	4,958,823	Jul 25 04:35 PM
Pilnik Richard D.	Director	Apr 07 '25	Option Exercise	2.11	24,000	50,640	312,995	Apr 08 04:41 PM
Giuffre Randall Michael	Director	Feb 13 '25	Option Exercise	2.56	17,000	43,570	392,412	Feb 18 04:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DMAC

DiaMedica Therapeutics Inc

Upgrade your FINVIZ experience